Fairfield, Bush & Co. Iovance Biotherapeutics, Inc. Transaction History
Fairfield, Bush & Co.
- $169 Billion
- Q1 2024
A detailed history of Fairfield, Bush & Co. transactions in Iovance Biotherapeutics, Inc. stock. As of the latest transaction made, Fairfield, Bush & Co. holds 21,450 shares of IOVA stock, worth $156,585. This represents 0.19% of its overall portfolio holdings.
Number of Shares
21,450
Previous 120
17775.0%
Holding current value
$156,585
Previous $976,000
32470.59%
% of portfolio
0.19%
Previous 0.0%
Shares
2 transactions
Others Institutions Holding IOVA
# of Institutions
305Shares Held
221MCall Options Held
3.05MPut Options Held
1.6M-
Vanguard Group Inc Valley Forge, PA24.9MShares$182 Million0.01% of portfolio
-
Mhr Fund Management LLC New York, NY24MShares$175 Million40.86% of portfolio
-
Black Rock Inc. New York, NY19.9MShares$145 Million0.01% of portfolio
-
Perceptive Advisors LLC New York, NY19.3MShares$141 Million5.99% of portfolio
-
Avoro Capital Advisors LLC New York, NY11.7MShares$85.4 Million2.09% of portfolio
About IOVANCE BIOTHERAPEUTICS, INC.
- Ticker IOVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 157,800,992
- Market Cap $1.15B
- Description
- Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment o...